diabetes

Latest news and analysis on diabetes

Equities

Structural tailwinds + category leadership = long runway for growth for this glucose monitoring company

The Continuous Glucose Monitor market is poised for structural growth, and we believe Dexcom is best positioned to dominate the growth cycle
Jacob Celermajer
Cordis Asset Management
Education

Ozempic – Is Novo Nordisk’s diabetes and weight loss drug a miracle or a menace?

In a society riddled with low self-esteem and mental health issues, weight loss can be a controversial and difficult topic. Pop culture and social media do more harm...
Ted Franks
Pengana Capital Group

From @morgans analyst, Scott Power Just back from the World Diabetes Conference in Melbourne

Livewire Equities
Livewire Equities
Livewire
3